BRPI0911476A2 - compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos - Google Patents

compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos

Info

Publication number
BRPI0911476A2
BRPI0911476A2 BRPI0911476-9A BRPI0911476A BRPI0911476A2 BR PI0911476 A2 BRPI0911476 A2 BR PI0911476A2 BR PI0911476 A BRPI0911476 A BR PI0911476A BR PI0911476 A2 BRPI0911476 A2 BR PI0911476A2
Authority
BR
Brazil
Prior art keywords
compounds
preparing
pharmaceutical composition
pyridazinone
treating
Prior art date
Application number
BRPI0911476-9A
Other languages
English (en)
Inventor
Joseph Berthel Steven
Haynes Nancy-Ellen
Sarabu Ramakanth
Qian Yimin
Robert Scott Nathan
Wright Tilley Jefferson
Apostle Mcdermott Lee
Francis Kester Robert
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of BRPI0911476A2 publication Critical patent/BRPI0911476A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"compostos derivados de piridazinona, composição farmacêutica contendo os mesmos e processo para a preparação dos referidos compostos" a presente invenção se refere a compostos de fórmula (i): (i) ' em que x, y, q e r1 a r3 são tais como definidos no relatório, bem como os seus sais farmaceuticamente aceitáveis , em que os substituintes são tais como aqueles expostos no relatório . estes compostos, e as composições farmacêuticas que os contêm, são de utilidade para o tratamento de enfermidades e distúrbios metabólicos tais como, por exemplo, diabetes mellitus do tipo ii .
BRPI0911476-9A 2008-04-16 2009-04-06 compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos BRPI0911476A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4531808P 2008-04-16 2008-04-16
US61/045,318 2008-04-16
US11465408P 2008-11-14 2008-11-14
US61/114,654 2008-11-14
PCT/EP2009/054058 WO2009127544A1 (en) 2008-04-16 2009-04-06 Pyridazinone glucokinase activators

Publications (1)

Publication Number Publication Date
BRPI0911476A2 true BRPI0911476A2 (pt) 2019-03-19

Family

ID=40666944

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911476-9A BRPI0911476A2 (pt) 2008-04-16 2009-04-06 compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos

Country Status (14)

Country Link
US (1) US8258134B2 (pt)
EP (1) EP2268633A1 (pt)
JP (1) JP5301655B2 (pt)
KR (1) KR101270389B1 (pt)
CN (1) CN102007116B (pt)
AR (1) AR071323A1 (pt)
AU (1) AU2009237792B2 (pt)
BR (1) BRPI0911476A2 (pt)
CA (1) CA2720559A1 (pt)
IL (1) IL207349A (pt)
MX (1) MX2010009922A (pt)
PE (1) PE20091725A1 (pt)
TW (1) TW200944517A (pt)
WO (1) WO2009127544A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
CA2676173A1 (en) * 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
KR101616139B1 (ko) 2008-02-29 2016-04-27 랜티우스 메디컬 이메징, 인크. 관류 영상화를 포함하는 용도를 위한 조영제
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
AU2011213568B2 (en) 2010-02-08 2016-05-12 Lantheus Medical Imaging, Inc. Methods and apparatus for synthesizing imaging agents, and intermediates thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TWI566663B (zh) * 2011-03-15 2017-01-11 鴻海精密工業股份有限公司 鎖扣組件、帶有鎖扣組件的載具及電路板固定系統
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
JP6506836B2 (ja) 2014-08-14 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
US10336730B2 (en) 2015-08-05 2019-07-02 Bristol-Myers Squibb Company Substituted glycine derived FXIA inhibitors
AR127064A1 (es) * 2021-09-15 2023-12-13 Hua Medicine Shanghai Ltd Prodroga de derivados de pirrolidona como activador de glucoquinasa
WO2024132901A1 (en) * 2022-12-19 2024-06-27 Syngenta Crop Protection Ag Microbiocidal pyridazine dihydrooxadiazine derivatives
AR132113A1 (es) * 2023-03-13 2025-05-28 Hua Medicine Shanghai Ltd Forma sólida de derivados de pirrolidona como activador de glucoquinasa

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1046139B (zh) 1999-03-29 2004-12-10 霍夫曼-拉罗奇有限公司 葡糖激酶活化剂
ATE304011T1 (de) * 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren
EP1282612B1 (en) 2000-05-03 2004-12-29 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
MXPA02010795A (es) 2000-05-08 2003-03-27 Hoffmann La Roche Activadores de glucocinasa de fenilamida sustituida por para-amino.
BR0110704A (pt) 2000-05-08 2003-01-28 Hoffmann La Roche Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
EP1341774B1 (en) 2000-12-06 2006-02-01 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
KR101018318B1 (ko) * 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Ｇｋ 활성제로서의 아미드 유도체
BR0309546A (pt) * 2002-04-26 2005-02-15 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
GB0210762D0 (en) * 2002-05-10 2002-06-19 Glaxo Group Ltd Compounds
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GT200300283A (es) * 2002-12-12 2004-07-14 Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
WO2004076420A1 (ja) 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
EP2048137A1 (en) 2004-02-18 2009-04-15 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents.
JP2007523905A (ja) 2004-02-18 2007-08-23 アストラゼネカ アクチボラグ 化合物
AU2005223610B2 (en) 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
PT1735322E (pt) 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
EA012204B1 (ru) 2004-04-21 2009-08-28 Прозидион Лимитед Три(цикло)замещённые амидные соединения
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
MX2007001650A (es) 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
AU2005311269B2 (en) 2004-12-03 2011-11-10 Transtech Pharma, Inc. Heteroaromatic glucokinase activators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
US20110053910A1 (en) 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
RU2420525C2 (ru) 2005-07-11 2011-06-10 Мицубиси Танабе Фарма Корпорейшн Производные оксимов и их получение
WO2007017649A1 (en) 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
AU2006285834A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
CA2626475A1 (en) 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
JP2009514836A (ja) 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
KR20080042286A (ko) * 2006-11-09 2008-05-15 주식회사 엘지생명과학 피리다지논 구조를 포함하는 캐스파제 저해제
CL2008002703A1 (es) * 2007-09-14 2009-11-20 Sumitomo Chemical Co Compuestos derivados de 1,4-dihidro-2h-piridazin-3-ona; composicion herbicida que comprende a dichos compuestos; metodo de control de malezas; uso de dichos compuestos para el control de malezas; y compuestos intermediarios.
JP5423679B2 (ja) * 2007-10-31 2014-02-19 日産化学工業株式会社 ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
EP2328586A2 (en) * 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase

Also Published As

Publication number Publication date
CN102007116A (zh) 2011-04-06
KR20100124328A (ko) 2010-11-26
WO2009127544A1 (en) 2009-10-22
US20090264434A1 (en) 2009-10-22
KR101270389B1 (ko) 2013-06-05
US8258134B2 (en) 2012-09-04
PE20091725A1 (es) 2009-11-13
EP2268633A1 (en) 2011-01-05
MX2010009922A (es) 2010-09-28
CA2720559A1 (en) 2009-10-22
TW200944517A (en) 2009-11-01
AR071323A1 (es) 2010-06-09
AU2009237792B2 (en) 2014-07-24
IL207349A0 (en) 2010-12-30
IL207349A (en) 2014-08-31
JP5301655B2 (ja) 2013-09-25
CN102007116B (zh) 2014-10-22
AU2009237792A1 (en) 2009-10-22
JP2011516592A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
BRPI0915592A2 (pt) composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii
BR112012027062A2 (pt) composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
BR112014009717A2 (pt) "derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica"
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
BR112014000713A2 (pt) derivados de indol substituído como moduladores de gama secretase
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
MX2010009922A (es) Activadores de piridazinona glucocinasa.
BR122017015106B8 (pt) estrutura de cristal de formula 1b e composição farmacêutica
BR112012014899A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
BR112014026383A2 (pt) derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl1
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BR112015018751A2 (pt) derivados de piridazinona macrocíclicos
BR112012030820A8 (pt) Derivados de aminopirimidina como moduladores de lrrk2, seu uso e composição que os compreende
BRPI0614168A2 (pt) Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
BRPI0908406B8 (pt) Derivados de quinoxalinona, processo para a preparação dos mesmos, seu uso e composição farmacêutica
BRPI0910832B8 (pt) derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.
BRPI0915942A2 (pt) método para produção de compostos medicinais contendo dabigatrana
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
BRPI0613570A8 (pt) composto ou um sal do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto.
AR072242A1 (es) Derivados de imidazopiridina, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neuromusculares.
BR112012018098A2 (pt) compostos de 4-fenoxi-nicotinamida ou 4-fenoxi-pirimidina -5-carboxamida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2516 DE 26-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]